Neuroblastoma
📧 Sign up to get email alerts when something new happens for Neuroblastoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-02-20Clinical Trial Update: Phase I Study of Umbilical Cord Blood Natural Killer (NK) Cell Therapy for Children With High-risk, R/R Neuroblastoma. [Phase 1]
Phase I trial evaluating umbilical cord blood-derived natural killer (NK) cell therapy in children with high-risk, relapsed/refractory neuro…
-
CLINICAL_TRIALS trial_result · 2025-02-17Clinical Trial Update: N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan [Phase 1]
The document reports the completion of a Phase 1 trial evaluating a combination of Difluoromethylornithine (DFMO) and celecoxib with cycloph…
-
CLINICAL_TRIALS research · 2025-02-17Clinical Trial Update: MCT for the Harvard/UCSF ROBIN Center [NA]
A clinical trial update showing recruitment is ongoing for an MCT study at the Harvard/UCSF ROBIN Center. The study targets glioma, pediatri…
-
CLINICAL_TRIALS research · 2025-02-12Clinical Trial Update: Accurate Diagnosis and Grading of Pediatric Solid Tumors Based on Pathological Large Models
A clinical trial from Xinhua Hospital and Shanghai Jiao Tong University aims to improve diagnosis and grading of pediatric solid tumors usin…
-
CLINICAL_TRIALS trial_result · 2025-02-11Clinical Trial Update: 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma [Phase 2]
A Phase 2 clinical trial evaluating Lutetium-177 DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma is current…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-02-10Clinical Trial Update: The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous CIK Cells [Phase 1, Phase 2]
An ongoing Phase 1/Phase 2 clinical trial at Siriraj Hospital is evaluating modified autologous cytokine-induced killer (CIK) cell immunothe…
-
CLINICAL_TRIALS research · 2025-02-07Clinical Trial Update: Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma [Phase 1]
Phase 1 clinical trial evaluating chimeric natural killer receptor-universal T cells for relapsed or refractory neuroblastoma. The study is …
-
CLINICAL_TRIALS research · 2025-02-05Clinical Trial Update: Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating Anti-GD2 CAR T cells in pediatric patients with high-risk or relapsed/refractory neuroblastoma and other…
-
CLINICAL_TRIALS trial_result · 2025-02-03Clinical Trial Update: Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg) [Phase 3]
Phase 3 clinical trial conducted by Institut Curie evaluating opsoclonus myoclonus syndrome in children with and without neuroblastoma; the …
-
CLINICAL_TRIALS research · 2025-02-03Clinical Trial Update: Pencil Beam Scanning Proton Beam Radiotherapy for the Management of Abdominal Neuroblastoma [NA]
The trial investigates pencil beam scanning proton beam radiotherapy for neuroblastoma and is currently not yet recruiting.
-
CLINICAL_TRIALS withdrawal · 2025-01-21Clinical Trial Update: 18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System [Phase 2]
The Phase 2 trial evaluating the radiopharmaceutical 18F-mFBG for neural crest tumors has been withdrawn.
-
CLINICAL_TRIALS research · 2025-01-14Clinical Trial Update: Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors [Phase 2]
Phase 2 pediatric trial evaluating palbociclib in combination with chemotherapy for recurrent or refractory solid tumors, including Ewing sa…
-
CLINICAL_TRIALS trial_result · 2025-01-01Clinical Trial Update: Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors [Phase 2]
Phase 2 trial evaluating neoadjuvant dual checkpoint inhibition with cryoablation in relapsed/refractory pediatric solid tumors has complete…
-
CLINICAL_TRIALS trial_result · 2025-01-01Clinical Trial Update: MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors [Phase 1]
Phase 1 trial completion evaluating MR-guided High Intensity Focused Ultrasound (HIFU) for relapsed or refractory pediatric solid tumors, in…
-
CLINICAL_TRIALS trial_result · 2024-12-20Clinical Trial Update: A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors [Phase 1, Phase 2]
Clinical trial evaluating idasanutlin in combination with chemotherapy or venetoclax in pediatric and young adult relapsed/refractory acute …
-
CLINICAL_TRIALS research · 2024-12-20Clinical Trial Update: A Study on the Efficacy of GD2-CAR T Cells in the Treatment of Neuroblastoma [EARLY_Phase 1]
An early Phase 1 clinical trial evaluating GD2-targeted CAR T cells for neuroblastoma is currently in the recruiting stage.
-
FDA approval · 2024-12-19FDA Approved: CYCLOPHOSPHAMIDE — Original Application (BluePoint Laboratories)
FDA approved BluePoint Laboratories' original ANDA for cyclophosphamide, establishing a generic version of the chemotherapy agent.
-
CLINICAL_TRIALS withdrawal · 2024-12-11Clinical Trial Update: 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma
This clinical trial evaluating 131I-MIBG therapy for relapsed/refractory neuroblastoma is no longer available; sponsored by UT Southwestern …
-
CLINICAL_TRIALS trial_result · 2024-11-20Clinical Trial Update: Chemotherapy in Treating Children With Neuroblastoma [Phase 1]
A Phase 1 trial evaluating chemotherapy in children with neuroblastoma has completed.
-
CLINICAL_TRIALS research · 2024-11-15Clinical Trial Update: 18F-mFBG LAFOV PET/CT Compared to 123I-mIBG Scintigraphy SPECT/CT for Evaluation of Children With Neuroblastoma [NA]
This clinical trial compares 18F-mFBG LAFOV PET/CT with 123I-mIBG SPECT/CT for evaluating neuroblastoma in children and is currently recruit…
-
CLINICAL_TRIALS trial_result · 2024-10-30Clinical Trial Update: Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products
Long-term follow-up results are reported for patients who received gene therapy or gene-marked products across several conditions, including…
-
CLINICAL_TRIALS trial_result · 2024-10-04Clinical Trial Update: Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta As Maintenance Therapy in Chinese Participants With High-Risk Neuroblastoma [Phase 1]
Phase 1 study evaluating the safety and pharmacokinetics of dinutuximab beta as maintenance therapy in Chinese participants with high-risk n…
-
CLINICAL_TRIALS trial_result · 2024-10-02Clinical Trial Update: GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2 [Phase 1]
Phase 1 clinical trial evaluating the GD2-SADA:177Lu-DOTA complex in GD2-expressing solid tumors is currently recruiting, including small ce…
-
CLINICAL_TRIALS trial_result · 2024-09-23Clinical Trial Update: Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib
This clinical trial update describes a real-world data collection study of lorlatinib in pediatric neuroblastoma. The study was terminated a…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) [Phase 2]
Phase 2 update on erdafitinib for FGFR-mutant relapsed or refractory pediatric cancers enrolled in the Pediatric MATCH trial; results were p…